Eldad Kepten's research while affiliated with Institut Curie and other places

Publications (13)

Article
Full-text available
REGEN-COV, a combination of the monoclonal antibodies casirivimab and imdevimab, has been approved as a treatment for high-risk patients infected with SARS-CoV-2 within five days of their diagnosis. We performed a retrospective cohort study, and used data repositories of Israel’s largest healthcare organization to determine the real-world effective...
Preprint
Full-text available
REGEN-COV, a combination of the monoclonal antibodies casirivimab and imdevimab, has been approved as a treatment for high-risk patients infected with SARS-CoV-2 within 5 days of their diagnosis. We used the data repositories of Israel’s largest healthcare organization to determine the real-world effectiveness of REGEN-COV treatment against COVID-1...
Article
Children unvaccinated against SARS-CoV-2 may still benefit through protection from vaccinated contacts. We estimated the protection provided to children through parental vaccination with the BNT162b2 vaccine. We studied households without prior infection, consisting of two parents and unvaccinated children, estimating the effect of parental vaccina...
Article
Full-text available
Background Methodologically rigorous studies on Covid-19 vaccine effectiveness (VE) in preventing SARS-CoV-2 infection are critically needed to inform national and global policy on Covid-19 vaccine use. In Israel, healthcare personnel (HCP) were initially prioritized for Covid-19 vaccination, creating an ideal setting to evaluate early real-world V...
Preprint
Full-text available
Background Methodologically rigorous studies on Covid-19 vaccine effectiveness (VE) in preventing SARS-CoV-2 infection are critically needed to inform national and global policy on Covid-19 vaccine use. In Israel, healthcare personnel (HCP) were initially prioritized for Covid-19 vaccination, creating an ideal setting to evaluate real-world VE in a...
Article
Background Preapproval trials showed that messenger RNA (mRNA)–based vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had a good safety profile, yet these trials were subject to size and patient-mix limitations. An evaluation of the safety of the BNT162b2 mRNA vaccine with respect to a broad range of potential adverse e...
Article
Full-text available
The BNT162b2 mRNA vaccine is highly effective against SARS-CoV-2. However, apprehension exists that variants of concern (VOCs) may evade vaccine protection, due to evidence of reduced neutralization of the VOCs B.1.1.7 and B.1.351 by vaccine sera in laboratory assays. We performed a matched cohort study to examine the distribution of VOCs in infect...
Preprint
Full-text available
The SARS-CoV-2 pandemic has been raging for over a year, creating global detrimental impact. The BNT162b2 mRNA vaccine has demonstrated high protection levels, yet apprehension exists that several variants of concerns (VOCs) can surmount the immune defenses generated by the vaccines. Neutralization assays have revealed some reduction in neutralizat...
Article
Background: As mass vaccination campaigns against coronavirus disease 2019 (Covid-19) commence worldwide, vaccine effectiveness needs to be assessed for a range of outcomes across diverse populations in a noncontrolled setting. In this study, data from Israel's largest health care organization were used to evaluate the effectiveness of the BNT162b...

Citations

... Interestingly, REGN-COV showed a major efficacy in serum antibodynegative patients or when viral load was higher at baseline [26]. Moreover, a retrospective cohort study determined the real-world effectiveness of REGEN-COV against COVID-19related hospitalization, severe disease and death [27]. The effectiveness of REGEN-COV was 56.4% in preventing COVID-19 hospitalization, 59.2% in preventing severe COVID-1 and 93.5% in preventing COVID-19 death in the 28 days after treatment. ...
... Hayek et al. (41) evaluated the protective effect of parental COVID-19 vaccination provided to children. They studied two periods separately-an early period (Alpha variant), and a late period (Delta variant). ...
... Breakthrough infections within 2-6 months following two doses of COMIRNATY or Spikevax are relatively low, and several studies have calculated that infections are less frequent in vaccinated healthy individuals (0.2-6.3% across studies) than in unvaccinated individuals (2.2-7.5% across studies) [75][76][77][78]. Taking into account these data, the rate of breakthrough infections detected in our cohort (six of 18; 33.33%), acquired a median time of approximately 3 months after receiving the booster dose, was considerably higher. ...
... 9 As patients became eligible for second doses, real-world VE estimates against hospitalisation due to COVID-19 approximated 52-92%. [10][11][12] UK estimates of three-dose VE against hospitalisation due to Omicron vary, ranging from 70 to 99%. 13 Early in 2021, the interval between first and second doses of COVID-19 vaccines was extended to 12 weeks in the UK, to prioritise first dose administration. 14 The booster vaccination program began in September 2021, was timed at 6-months after completion of the primary course, and prioritised the most vulnerable: all adults aged ≥50 years, and those in clinical risk groups. ...
... Ongoing vaccination programs have provided data on COVID-19 vaccine effectiveness against several SARS-CoV-2 variants in a "real-life" setting (Table 1). Data from the mass vaccination campaign in Israel suggest that, consistent with in vitro studies, effectiveness of the BNT162b2 mRNA vaccine against alpha is high, with studies carried out during the alpha-dominant period demonstrating vaccine effectiveness after the primary regimen of BNT162b2 up to 94.5% against SARS-CoV-2 infection (146,147). Similarly, results obtained during the mass vaccination campaign in Scotland also indicate effectiveness against confirmed alpha infections of 92% for BNT162b2 and 73% for ChAdOx1 nCoV-19 after the primary regimen (148). In England, effectiveness of the primary regimen of BNT162b2 or ChAdOx1 nCoV-19 was 93.7% and 74.5%, respectively, against symptomatic COVID-19 (149). ...
... FDA approval of the LNP nucleic acid therapeutic patisiran (2018) and COVID-19 vaccines BNT162b2 and mRNA-1273 (2021, 2022) have paved the way in understanding baseline LNP pharmacokinetics and pharmacodynamics in humans [64]. Many studies have found LNPs to be effective, generally safe, and well-tolerated [65][66][67], making LNPs an attractive delivery platform. In general, LNPs comprise four key elements: an ionizable lipid, helper lipid, cholesterol, and poly(ethylene glycol) (PEG)-functionalized lipids. ...
... Initially, these vaccines proved to be highly effective in preventing SARS-CoV-2 infection and severe illness and death [4][5][6][7]. However, in a phase of waning immunity, breakthrough infections have been reported [8][9][10][11][12][13][14]. These numbers further increased with the emergence of new virus variants, especially the latest variant of concern (VOC), Omicron. ...
... An analysis of 1181 samples collected in East England in 2020 revealed 11,216 within-host variants (on average 9,5 iSNVs per sample) containing 7102 single-nucleotide substitutions, 3223 small deletions, 542 small insertions and 349 multi-nucleotide variants [9]. The most intriguing observation, also made my others, was the dominance of cytidine to uridine transitions (C→U; 47,9%) in the 5´-3´sense strand while the opposite change from guanosine to adenosine (G→A) in the 3´-5´anti-sense strand accounted for only 5,3% [9] [37] [42] [43]. Since this strand asymmetry is more pronounced in SARS-CoV-2 compared to SARS-CoV-1 and MERS, and absent in bat coronaviruses [42], it may arise from the replication of the virus in human cells. ...
... 4 Another study showed significant association between pre-infection HbA1c and risk of severe COVID-19 despite adjustment for demographics, chronic illness, diabetes complications or treatment. 5 There was a slight decline in review of metformin and compliance with recommended hyperglycaemia management. The reasons for this are unclear, though we note that the decline is not statistically significant, and a larger sample size may have given us more representative information. ...
... Knowing mRNA vaccination-related secondary effects is essential for radiologists and oncologists to prevent false interpretations during diagnostic imaging procedures [8]. ...